This site is intended for US audiences only. If you are a resident of the European Union, please click here for the EU version of our site.
Who to Test for PNH: Unexplained Venous or Arterial Thrombosis
Venous and arterial thromboses account for approximately 40% to 67% of PNH-related deaths.1 Venous thromboembolism (VTE) is 62 times more likely in patients with PNH vs the general population.
Thromboembolism With ANY of the Following Risk Factors Should Raise the Suspicion for PNH2,3
Atypical sites:
- All patients should be tested
Typical sites, including one or more of the following:
- Prior thromboembolism in typical sites
- Evidence of hemolysis
- Accompanying bone marrow failure disorder
- While receiving anticoagulant therapy
- Anemia, thrombocytopenia, and/or granulocytopenia
In patients with thromboembolism in atypical or typical sites and additional risk factors, add PNH flow cytometry to your hypercoagulation panel.
Next: Full Clinical Assessment
1. Hillmen P, Muus P, Dührsen U, et al. Blood. 2007;110:4123-4128. 2. Parker C, Omine M, Richards S, et al; for The International PNH Interest Group. Blood. 2005;106:3699-3709.
3. Borowitz MJ, Craig FE, DiGiuseppe JA, et al; for Clinical Cytometry Society. Cytometry Part B Clin Cytom. doi:10.1002/cyto.b.20525.
3. Borowitz MJ, Craig FE, DiGiuseppe JA, et al; for Clinical Cytometry Society. Cytometry Part B Clin Cytom. doi:10.1002/cyto.b.20525.
PNH Facts:
35% of patients with PNH die within 5 years of diagnosis. Thrombosis is the leading cause of death.
Visit the PNH Education Center for case studies, videos, and brochures dealing with a wide range of PNH topics.